Anderson Ribeiro, Aline Ferreira and Henryk Trelinski of Souto Correa Advogados contributed to the preparation of this article.

Foreign companies have long faced a practical challenge under Brazil’s access and benefit-sharing (“ABS”) regime: although registration obligations apply to activities involving Brazilian genetic heritage, foreign legal entities still cannot register directly in SisGen, Brazil’s electronic system used to register activities involving Brazilian genetic heritage and associated traditional knowledge.

Two developments in June 2026 sought to address this issue.  While Brazil’s Genetic Heritage Management Council (“CGen”) postponed approval of the long-awaited foreign-user functionality in SisGen 3.0, the Brazilian Government simultaneously introduced a new mechanism that may enable foreign companies to register through Brazilian institutions.

Taken together, these developments suggest that Brazil is pursuing a dual-track approach: while direct foreign access to SisGen remains under development, foreign companies may soon have an alternative pathway to comply with Brazilian registration requirements.

Foreign Entities still cannot access SisGen directly

Brazil’s ABS framework requires the registration of activities involving access to Brazilian genetic heritage and associated traditional knowledge.  However, SisGen continues to operate under a structure designed primarily for Brazilian users and institutions, and foreign legal entities still cannot independently register activities or carry out regularization measures through the system.

This limitation has long created practical challenges for foreign companies seeking to comply directly with Brazilian ABS requirements.  As a result, many organizations have been awaiting the implementation of the foreign-user functionality that forms part of the planned SisGen 3.0 upgrade.

Against this backdrop, stakeholders were closely following the 45th Ordinary Meeting of CGen, held on June 10-11, 2026, where updates regarding SisGen 3.0 were on the agenda.

The meeting, however, did not result in approval of the foreign-user functionality. According to information presented during the meeting, the matter was postponed to allow completion of additional technical testing before the functionality is submitted to CGen for approval.

As a result, the next Ordinary CGen Meeting, currently scheduled for September 2026, is expected to be the next significant milestone for consideration of the foreign-user component of SisGen 3.0.

Government introduces Interim Registration Mechanism

While implementation of direct foreign access remains pending, the Brazilian Government has moved forward with an alternative registration mechanism.

On June 10, 2026, Decree No. 13.014/2026 amended the regulatory framework governing Brazil’s ABS regime to allow foreign legal entities to register access activities in SisGen through a Brazilian scientific and technological institution by means of a “term of association for registration purposes.”  The Decree expressly allows such arrangements even where no scientific partnership exists between the parties.

According to the Decree, this mechanism is intended to facilitate compliance with registration obligations, ensure traceability of access activities, formalize institutional interaction with competent authorities, and support monitoring of information reported in SisGen.

Under this framework, the Brazilian institution is responsible for carrying out the registration within SisGen based on information provided by the foreign entity.  The foreign legal entity, however, remains responsible for the accuracy of the information submitted and for compliance with applicable legal obligations.

From a practical perspective, the Decree creates a new route for foreign entities to meet Brazil’s registration requirements pending implementation of direct foreign access to SisGen.  Nevertheless, the extent to which this pathway will be used in practice will depend on its operational implementation within SisGen and any further guidance issued by Brazilian authorities.

Why this matters?

The delay in approving SisGen 3.0 does not alter the underlying legal obligations applicable to companies that have accessed Brazilian genetic heritage or associated traditional knowledge.  Foreign entities remain subject to Brazil’s ABS framework and may still need to evaluate whether their activities trigger registration obligations.

The future release of the SisGen 3.0 foreign-user functionality remains important because it is expected to activate a specific regularization period for foreign entities.  Under current regulations, foreign legal entities will have one year from the availability of the foreign-user functionality to regularize activities that were carried out without prior registration.

Crucially, Decree No. 13.014/2026 does not appear to alter this regulatory timeline.  The launch of the foreign-user functionality therefore remains the key triggering event for the start of the one-year regularization period.

For now, the Brazilian ABS framework remains in a transitional phase.  While the legal obligation to register qualifying activities is already in force, the mechanism for direct compliance by foreign legal entities remains unavailable, and the timeline for its implementation continues to depend on the development and approval of SisGen 3.0.

***

Covington & Burling LLP is closely tracking developments relating to SisGen 3.0 and the evolving compliance framework for foreign entities under Brazil’s ABS regime.  Together with the Brazilian firm Souto Correa, we advise clients on assessing Brazilian ABS obligations, preparing for potential regularization requirements, and navigating registration pathways under SisGen.

If you have any questions, do not hesitate to reach out to Bart Van Vooren (bvanvooren@cov.com) and Anderson Ribeiro (anderson.ribeiro@soutocorrea.com).

Photo of Bart Van Vooren Bart Van Vooren

Bart Van Vooren, partner leads a dynamic practice at the intersection of EU regulatory law, global health, and biodiversity law. In these fields, he advises innovative pharmaceutical, food, cosmetic and technology companies on complex EU and global regulatory, compliance and policy assignments.

Bart…

Bart Van Vooren, partner leads a dynamic practice at the intersection of EU regulatory law, global health, and biodiversity law. In these fields, he advises innovative pharmaceutical, food, cosmetic and technology companies on complex EU and global regulatory, compliance and policy assignments.

Bart holds a Ph.D. in EU and International Law and was a professor of EU law until 2013. During that time, he wrote the first-ever handbook with Cambridge University Press on “EU External Relations Law” (2014). He then transitioned to private practice, and frequently acted for the Belgian government before the EU Court of Justice (e.g. C-16/16P Belgium vs Commission). Bart joined Covington in 2016, leading some of our most consequential EU litigation proceedings (e.g. C-311/18 “Schrems II”) over the years.  Having handled nearly 50 cases before the EU Court, he’s uniquely qualified to support our corporate clients in our most high-stakes disputes. Recent examples include T-189/21 Aloe Vera of Europe v Commission (which we won, so the Commission decided to appeal); as well as T-201/21 Covington & Burling and Van Vooren v Commission (which we also won, and hence is also on appeal).

As a pioneer in biodiversity law, over the past 15 years Bart has built a unique, global practice on Access and Benefit-Sharing (ABS) laws under the Convention on Biological Diversity, the Nagoya Protocol, the Plant Treaty, the High Seas Treaty and the WHO Pandemic Agreement. ABS compliance is critical when sourcing biological materials for life sciences R&D and I work with many of the world’s innovative life sciences companies on the whole range of e.g. transactional, contractual, compliance, IP, (EU) regulatory and litigation work relating to ABS. As biodiversity has increasingly become identified as a major commercial and financial risk to companies, so has the practice expanded to e.g. biodiversity credit markets, biodiversity insurance, biodiversity claims and advertising, and so on. Since April 2025, Bart has been appointed as the industry representative to the Steering Committee of the UN Biodiversity Fund that seeks funding from the private sector for biodiversity conservation and restoration.

Bart also pioneered our global health practice. He has advised pharmaceutical clients on seasonal and pandemic influenza since 2016. Since then, this practice area expanded to cover all matters relating to infectious diseases, and as of 2020, emergency preparedness and response (eg. WHO prequalification, International Coordination Group negotiations, Emergency Use Listing, International Health Regulations Rev 2024). He has been the pharmaceutical industry’s lead lawyer advising on the WHO Pandemic Treaty negotiations, adopted on 14 May 2025. Currently, he continues to advise on the work of the Intergovernmental Working Group (“IGWG”) teasing out the technical details of the “Pathogen Access and Benefit-Sharing System” intended to create legally binding obligations on companies to commit vaccines, therapeutics and diagnostics in case of a new global health emergency.

In Chambers rankings, clients have kindly described Bart as “very knowledgeable, action-focused and service-focused lawyer”, adding that he “really tries to find a way of working through challenges”, am “customer-oriented” and provide “sound advice and reasonable options for our business with pros and cons.”

Finally, Bart has an active pro bono practice assisting NGOs defending the human rights of persons with a disability through strategic litigation before the EU Court.

Photo of Yuliya Gevrenova Yuliya Gevrenova

Yuliya Gevrenova is an associate in the Life Sciences Practice Group. She advises clients across a wide range of regulatory, compliance and procedural issues, focusing on EU and Public International law.

Yuliya assists multinational companies in the food, feed, pharmaceutical and cosmetics sectors…

Yuliya Gevrenova is an associate in the Life Sciences Practice Group. She advises clients across a wide range of regulatory, compliance and procedural issues, focusing on EU and Public International law.

Yuliya assists multinational companies in the food, feed, pharmaceutical and cosmetics sectors to navigate complicated legal frameworks, including:

International Health law, including the impact of the WHO Pandemic treaty, the application of the International Health Regulations and the Pandemic Influenza Preparedness Framework.
International Environmental law, including issues of access and benefit sharing under the Convention on Biological Diversity and the Nagoya protocol.
Food law, including labelling and claims; coordination with national authorities during withdrawals and recalls; special rules on flavorings and enzymes, as well as GMOs and NGTs.
Chemicals (REACH, plastics, pollutants, etc.) and Environmental regulations (CSDDD, Wastewater Directive, green washing, etc.).
Animal health issues, including animal testing, transportation and feed.

As part of her pro bono practice, Yuliya advises on complex litigation strategies aimed at defending the rights of people with mental disabilities.